Jun. 4 at 4:06 PM
Remember this past Sunday at ASCO? The entire auditorium erupted into a standing ovation for
$RVMD. Their "homerun" hazard ratio printed at **0.40**, completely doubling pancreatic cancer survival to 13.2mo vs 6.6mo. It was history in the making. 🚀
Now look at
$SLS, the FDA approval bar for their Phase 3 REGAL trial is an
$HR of 0.636. soo if Best Available Therapy (BAT) holds at the historical 8.0 months:
**The "Good" Win:** GPS hits **12.6 months** HR = 0.636 rock-solid FDA approval.
**THE GRAND SLAM:** If GPS hits the **20 to 24-month mark** (just like it did in Phase 2), the HR plummets **0.33 to 0.40 range** matches or beats the
$RVMD bar, flips the AML world on its f*ckin head, and SLS$ goes to the moon. 🌌
$RVMD sits at
$33.6B
$SLS now has 196.6M shares outstanding—making its share structure incredibly close to
$RVMD. If we print a grand slam 0.40s and hit full valuation parity with
$RVMD,
$SLS doesn't just hit
$25 or
$50... mathematically, we fly straight to
$171.00
